Please login to the form below

Not currently logged in
Email:
Password:

MorphoSys appoints Dr Markus Enzelberger as CSO

He succeeds Dr Marlies Sproll who resigns

Markus EnzelbergerGerman biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation.

Sproll will remain with the company on a part-time basis as a special advisor to chief executive officer Dr Simon Moroney, however Dr Enzelberger, who joined MorphySys in 2002, has served as its interim CSO since April this year.

Dr Enzelberger has served in various capacities at MorphoSys including senior vice president, discovery, alliances and technologies, taking responsibility for the drug discovery activities for proprietary and partnered programmes.

Dr Gerald Moller, supervisory board chairman, MorphoSys, said: “Dr Enzelberger is the perfect person to take over the CSO role at MorphoSys on a permanent basis.

“Drawing on his vast scientific expertise and experience in the management of antibody technology, research and discovery, he will continue to drive the group’s early-stage research activities with the goal of fuelling the company’s R&D pipeline with novel drug candidates in oncology and immunology.”

9th November 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics